NDAINJECTIONINJECTABLE
Approved
Oct 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
XENON XE 133 (xenon xe-133) by Lantheus Medical Imaging is radiopharmaceutical activity [moa]. First approved in 1974.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Xenon XE-133 is a radiopharmaceutical injectable administered for diagnostic imaging purposes. It works through radiopharmaceutical activity to visualize and assess organ function and blood flow. This legacy diagnostic agent has been a foundational tool in nuclear medicine for nearly 50 years.
LOE Approaching
As a 50-year-old diagnostic agent approaching loss of exclusivity, the brand team is likely small and focused on operational efficiency and quality compliance rather than growth initiatives.
Mechanism of Action
Radiopharmaceutical Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Xenon XE-133 positions you in a high-compliance, quality-driven environment where expertise in manufacturing, partner management, and regulatory maintenance are valued. This role suits professionals seeking stability and deep technical mastery over rapid career advancement.
International License Partner Quality Specialist
Quality Assurance
Worked on XENON XE 133 at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.